BeOne Medicines (ONC) Short-Term Debt issuances (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Short-Term Debt issuances of $58.2 million for Q1 2026, down 66.34% year-over-year from $172.9 million in Q1 2025, and down 92.43% quarter-over-quarter from $769.0 million in Q4 2025.
BeOne Medicines (ONC) Short-Term Debt issuances (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Short-Term Debt issuances for 8 consecutive years, with $58.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-Term Debt issuances fell 66.34% year-over-year to $58.2 million; the TTM figure through Mar 2026 stood at $930.1 million (down 10.67% YoY), while the FY2025 annual figure was $1.0 billion, up 20.33% from the prior year.
- Short-Term Debt issuances slipped to $58.2 million in Q1 2026 per ONC's latest filing, from $769.0 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $769.0 million in Q4 2025 and bottomed at -$2.3 million in Q3 2023.
- Historically, Short-Term Debt issuances has averaged $192.7 million across 5 years, with a median of $107.4 million in 2023.
- Annual changes were most pronounced in 2023 — Short-Term Debt issuances plunged 107.56% — and 2024, when it jumped 373.85%.
- BeOne Medicines' Short-Term Debt issuances stood at $271.7 million in 2022, then plunged by 44.78% to $150.0 million in 2023, then surged by 373.85% to $710.8 million in 2024, then increased by 8.19% to $769.0 million in 2025, then slumped by 92.43% to $58.2 million in 2026.
- Business Quant data shows ONC's Short-Term Debt issuances at $58.2 million in Q1 2026, $769.0 million in Q4 2025, and $102.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.20 Mn |
| Mar 31, 2026 | 58.20 Mn |
| Dec 31, 2025 | 769.00 Mn |
| Dec 31, 2025 | 769.00 Mn |
| Jun 30, 2025 | 102.86 Mn |
| Jun 30, 2025 | 102.86 Mn |
| Mar 31, 2025 | 172.92 Mn |
| Mar 31, 2025 | 172.92 Mn |
| Dec 31, 2024 | 710.78 Mn |
| Dec 31, 2024 | 710.78 Mn |
| Jun 30, 2024 | 157.49 Mn |
| Jun 30, 2024 | 157.49 Mn |
| Dec 31, 2023 | 150.00 Mn |
| Dec 31, 2023 | 150.00 Mn |
| Sep 30, 2023 | -2.27 Mn |
| Sep 30, 2023 | -2.27 Mn |
| Jun 30, 2023 | 111.85 Mn |
| Jun 30, 2023 | 111.85 Mn |
| Mar 31, 2023 | 50.00 Mn |
| Mar 31, 2023 | 50.00 Mn |